1283761-17-0

Upstream product

• 1083326-75-3 N-[2-(methyloxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-pyridinyl]methanesulfonamide 
• 1245465-20-6 6-bromo-4-{5-[(2,2-dimethyl-4-morpholinyl)methyl]-1,3,4-oxadiazol-2-yl}-1-(phenylsulfonyl)-1H-indazole 
• 1083327-58-5 N-[5-bromo-2-(methyloxy)-3-pyridinyl]methanesulfonamide 
• 152684-30-5 5-bromo-2-methoxy-3-nitropyridine 
• 67443-38-3 5-bromo-2-chloro-3-nitropyridine 
• 147688-58-2 2,2-dimethyl-morpholine 
• 893440-50-1 2-(methyloxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-pyridinamine 
• 884495-39-0 5-bromo-2-(methyloxy)-3-pyridinamine 
• 1245464-62-3 6-bromo-4-[5-(chloromethyl)-1,3,4-oxadiazol-2-yl]-1-(phenylsulfonyl)-1H-indazole 

Relevant academic research and scientific papers

Indazole derivatives for use in the treatment of influenza virus infection

The present invention is directed to compounds for use in the treatment or prevention of influenza virus infection.

4-OXADIAZOL-2 -YL- INDAZOLES AS INHIBITORS OF P13 KINASES

The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.